{"id":"mim-d3-ophthalmic-solution","safety":{"commonSideEffects":[{"rate":"null","effect":"Eye irritation"}]},"_chembl":{"chemblId":"CHEMBL2108251","moleculeType":"Oligosaccharide"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting GRK1, MIM-D3 Ophthalmic Solution reduces the degradation of rhodopsin, a key protein in the visual transduction pathway, thereby preserving vision in patients with retinal diseases.","oneSentence":"MIM-D3 Ophthalmic Solution is a small molecule that targets the rhodopsin kinase (GRK1) to treat retinal diseases.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:21:24.895Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of Leber congenital amaurosis due to RPE65 mutations"}]},"trialDetails":[{"nctId":"NCT01257607","phase":"PHASE2","title":"Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye","status":"COMPLETED","sponsor":"Mimetogen Pharmaceuticals USA, Inc.","startDate":"2010-11","conditions":"Dry Eye","enrollment":150},{"nctId":"NCT01960010","phase":"PHASE3","title":"A Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye","status":"COMPLETED","sponsor":"Mimetogen Pharmaceuticals USA, Inc.","startDate":"2013-10","conditions":"Dry Eye Syndromes","enrollment":403},{"nctId":"NCT02665234","phase":"PHASE3","title":"A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease","status":"COMPLETED","sponsor":"Mimetogen Pharmaceuticals USA, Inc.","startDate":"2016-01","conditions":"Keratoconjunctivitis Sicca","enrollment":400},{"nctId":"NCT02634853","phase":"PHASE3","title":"A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye","status":"COMPLETED","sponsor":"Mimetogen Pharmaceuticals USA, Inc.","startDate":"2015-12","conditions":"Keratoconjunctivitis Sicca","enrollment":429}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tavilermide Ophthalmic Solution"],"phase":"phase_3","status":"active","brandName":"MIM-D3 Ophthalmic Solution","genericName":"MIM-D3 Ophthalmic Solution","companyName":"Mimetogen Pharmaceuticals USA, Inc.","companyId":"mimetogen-pharmaceuticals-usa-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MIM-D3 Ophthalmic Solution is a small molecule that targets the rhodopsin kinase (GRK1) to treat retinal diseases. Used for Treatment of Leber congenital amaurosis due to RPE65 mutations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}